Ticker LaunchReverse merger · Completed · SPRY
ARS Pharmaceuticals, Inc.
Reverse merger with Silverback Therapeutics, Inc. (SBTX)
ARS Pharmaceuticals, Inc. merged into Silverback Therapeutics, Inc. (SBTX), a Nasdaq-listed biotech with cash and securities that merged with ARS, in a reverse merger that takes the private company public. The deal was announced on Jul 21, 2022 and closed on Nov 8, 2022. The combined company trades as ARS Pharmaceuticals, Inc. (SPRY) on Nasdaq.
ARS Pharmaceuticals is a biopharmaceutical company developing neffy, a needle-free epinephrine nasal spray for emergency treatment of Type I allergic reactions including anaphylaxis. The product was under FDA review at closing, with a decision date expected mid-2023.
- Status
- Completed
- Private company
- ARS Pharmaceuticals, Inc.
- Public company
- Silverback Therapeutics, Inc. (SBTX)
- Public company business before
- Nasdaq-listed biotech with cash and securities that merged with ARS
- Announced
- Jul 21, 2022
- Closed
- Nov 8, 2022
- Combined company
- ARS Pharmaceuticals, Inc. (SPRY)
- Exchange
- Nasdaq
- Sector
- Biotech & pharma
More on this deal for subscribers
- Ownership split between private and public holders
- Analyst notes from the filings
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Closing 8-K Nov 8, 2022
- Closing press release
- Announcement press release
- All filings on EDGAR CIK 1671858
Other completed reverse mergers
- Exworth Union Incinto Strategic Acquisitions, Inc. · Dec 22, 2022
- Kineta Operating, Inc. (Kineta)into Yumanity Therapeutics, Inc. · Dec 16, 2022
- AmeriGuard Security Services, Inc.into Health Revenue Assurance Holdings, Inc. · Dec 9, 2022
- Renewable Innovations, Inc.into Nestbuilder.com Corp. · Dec 1, 2022
- Fintech Scion Limitedinto HWGC Holdings Limited · Nov 30, 2022
- Gix Media Ltd.into Viewbix Inc. · Sep 19, 2022